Sumitomo Pharma Co., Ltd. logo

Sumitomo Pharma Co., Ltd.

4506.T

JPXHealthcareDrug Manufacturers - Specialty & Generic

Latest quote

¥1,418

+¥6.50 · +0.46%

Aug 24, 3:30 PM JST

4506.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
JP
CEO
Toru Kimura
Listed since
Jan 4, 2000
Employees
3,123

Market position

Day range

Current ¥1,418

52-week range

Current ¥1,418

Open
¥1,418.5
Previous close
¥1,411.5
Volume
2.26M
0.43× average
Average volume
5.27M
Average daily volume
Market cap
636.11B JPY
Beta
0.46
Market reference 1
50-day average
¥1,383.56
+2.49% above average
200-day average
¥1,951.62
-27.34% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
5.07×
P/B (TTM)
1.51×
P/S (TTM)
1.34×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
54.99%
Operating margin
10.05%
Net margin
23.73%

Financial health

Debt / equity
0.39×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends83%16%-50%-117%Gross margin, FY2022: 66.28%Gross margin, FY2023: 61.73%Gross margin, FY2024: 49.94%Gross margin, FY2025: 56.51%Gross margin, FY2026: 56.67%Operating margin, FY2022: 10.10%Operating margin, FY2023: 2.02%Operating margin, FY2024: -0.47%Operating margin, FY2025: 5.62%Operating margin, FY2026: 11.11%Net margin, FY2022: 10.07%Net margin, FY2023: -13.41%Net margin, FY2024: -100.13%Net margin, FY2025: 5.93%Net margin, FY2026: 23.58%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 66.28%. Gross margin FY2023 61.73%. Gross margin FY2024 49.94%. Gross margin FY2025 56.51%. Gross margin FY2026 56.67%. Operating margin FY2022 10.10%. Operating margin FY2023 2.02%. Operating margin FY2024 -0.47%. Operating margin FY2025 5.62%. Operating margin FY2026 11.11%. Net margin FY2022 10.07%. Net margin FY2023 -13.41%. Net margin FY2024 -100.13%. Net margin FY2025 5.93%. Net margin FY2026 23.58%.

Income trends

Revenue

453.29B JPY+13.66%

Operating income

50.34B JPY+124.51%

Net income

106.87B JPY+352.17%
Income trends across reported periods647.54B JPY297.53B JPY−52.47B JPY−402.47B JPYRevenue, FY2022: 560.04B JPYRevenue, FY2023: 555.54B JPYRevenue, FY2024: 314.56B JPYRevenue, FY2025: 398.83B JPYRevenue, FY2026: 453.29B JPYOperating income, FY2022: 56.55B JPYOperating income, FY2023: 11.2B JPYOperating income, FY2024: −1.48B JPYOperating income, FY2025: 22.42B JPYOperating income, FY2026: 50.34B JPYNet income, FY2022: 56.41B JPYNet income, FY2023: −74.51B JPYNet income, FY2024: −314.97B JPYNet income, FY2025: 23.63B JPYNet income, FY2026: 106.87B JPYFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 560.04B JPY. Revenue FY2023 555.54B JPY. Revenue FY2024 314.56B JPY. Revenue FY2025 398.83B JPY. Revenue FY2026 453.29B JPY. Operating income FY2022 56.55B JPY. Operating income FY2023 11.2B JPY. Operating income FY2024 −1.48B JPY. Operating income FY2025 22.42B JPY. Operating income FY2026 50.34B JPY. Net income FY2022 56.41B JPY. Net income FY2023 −74.51B JPY. Net income FY2024 −314.97B JPY. Net income FY2025 23.63B JPY. Net income FY2026 106.87B JPY.
Metric (JPY)FY2026FY2025FY2024FY2023FY2022
Revenue453.29B JPY398.83B JPY314.56B JPY555.54B JPY560.04B JPY
Cost of goods sold196.4B JPY173.46B JPY157.48B JPY212.6B JPY188.86B JPY
Gross profit256.89B JPY225.38B JPY157.08B JPY342.95B JPY371.18B JPY
Research and development44B JPY49.87B JPY112.64B JPY131.86B JPY94.9B JPY
Selling, general, and administrative162.56B JPY160.39B JPY397.71B JPY339.21B JPY217.34B JPY
Operating expenses206.55B JPY202.96B JPY158.55B JPY331.74B JPY314.62B JPY
Interest income3.2B JPY890M JPY2.02B JPY4.51B JPY183M JPY
Interest expense10.19B JPY8.56B JPY4.28B JPY3.16B JPY3.05B JPY
Depreciation and amortization20.79B JPY25.56B JPY37.77B JPY41.26B JPY38.35B JPY
Operating income50.34B JPY22.42B JPY−1.48B JPY11.2B JPY56.55B JPY
Net income106.87B JPY23.63B JPY−314.97B JPY−74.51B JPY56.41B JPY

Company facts updated Aug 24, 2026.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

¥28.00

2022 complete year+47.4% since 2018

Corporate action history

Dividend

Ex-dividend Mar 30, 2023

¥7.00

Semi-Annual

Record Mar 31, 2023 · Payment Jun 28, 2023

Dividend

Ex-dividend Sep 29, 2022

¥14.00

Irregular

Record Sep 30, 2022 · Payment Dec 1, 2022

Dividend

Ex-dividend Mar 30, 2022

¥14.00

Semi-Annual

Record Mar 31, 2022 · Payment Jun 24, 2022

Dividend

Ex-dividend Sep 29, 2021

¥14.00

Monthly

Record Sep 30, 2021 · Payment Dec 1, 2021

Dividend

Ex-dividend Mar 30, 2021

¥14.00

Semi-Annual

Record Mar 31, 2021 · Payment Jun 25, 2021

Dividend

Ex-dividend Sep 29, 2020

¥14.00

Irregular

Record Sep 30, 2020 · Payment Dec 1, 2020

4506.T peers

Continue in GoAI

Research 4506.T

research.disclaimer